文献速递消化系统肿瘤

CAPRI-GOIM试验:液体活检RAS检测与mCRC一线西妥昔单抗联合FOLFIRI疗效相关

RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
PubMed 文献 · Ann Oncol · 2018-01-01

CAPRI-GOIM试验中340例KRAS外显子2野生型mCRC患者接受一线西妥昔单抗联合FOLFIRI,其中92例同时有肿瘤NGS和基线血浆BEAMing检测数据。组织与血浆RAS检测一致率78.3%,RAS突变患者按组织和液体活检评估的无进展生存期和总生存期均相近,液体活检RAS检测与组织检测结果相似。

要点

  • 液体活检RAS检测与组织NGS检测一致率为78.3%。
  • RAS突变患者按组织(7.9 vs 12.6个月)和液体活检(7.8 vs 13.8个月)评估的无进展生存期相近。
  • RAS突变患者按组织和血浆评估的总生存期也相近。

核心结论

  • 在mCRC患者接受一线抗EGFR单抗治疗时,液体活检RAS检测与组织检测结果相似。

研究设计与样本

  • CAPRI-GOIM试验中340例KRAS外显子2野生型mCRC患者接受一线西妥昔单抗联合FOLFIRI,其中92例同时有肿瘤NGS和基线血浆BEAMing数据。
  • 肿瘤样本回顾性NGS评估,基线血浆用BEAMing检测KRAS和NRAS突变,不一致病例用ddPCR或深度测序解决。

主要发现

  • 组织和血浆检测均识别33/92例(35.9%)RAS突变,一致率78.3%。
  • 10例组织突变血浆野生型,另10例组织野生型血浆突变。
  • 组织突变血浆野生型中2/10例经ddPCR检测出血浆RAS突变。
  • 组织野生型血浆突变病例经ddPCR或深度测序确认肿瘤RAS突变,等位基因频率0.15%~1.15%。
  • RAS突变与野生型患者中位无进展生存期:组织7.9 vs 12.6个月(P=0.004),液体活检7.8 vs 13.8个月(P<0.001)。

关键数值与推荐

  • 组织和血浆检测识别RAS突变均为33/92例(35.9%)。
  • 组织与血浆RAS检测一致率78.3%。
  • 组织检测RAS突变 vs 野生型中位无进展生存期7.9 vs 12.6个月(P=0.004)。
  • 液体活检RAS突变 vs 野生型中位无进展生存期7.8 vs 13.8个月(P<0.001)。
  • 组织检测RAS突变 vs 野生型中位总生存期22.1 vs 35.8个月(P=0.016)。

临床怎么用

  • 液体活检RAS检测可作为mCRC患者组织检测的替代方法,与组织检测结果相似。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liquid biopsy is an alternative to tissue for RAS testing in metastatic colorectal carcinoma (mCRC) patients. Little information is available on the predictive role of liquid biopsy RAS testing in patients treated with first-line anti-EGFR monoclonal antibody-based therapy. PATIENTS AND METHODS: In the CAPRI-GOIM trial, 340 KRAS exon-2 wild-type mCRC patients received first-line cetuximab plus FOLFIRI. Tumor samples were retrospectively assessed by next generation sequencing (NGS). Baseline plasma samples were analyzed for KRAS and NRAS mutations using beads, emulsion, amplification, and magnetics digital PCR (BEAMing). Discordant cases were solved by droplet digital PCR (ddPCR) or deep-sequencing. RESULTS: A subgroup of 92 patients with available both NGS data on tumor samples and baseline plasma samples were included in this study. Both NGS analysis of tumor tissue and plasma testing with BEAMing identified RAS mutations in 33/92 patients (35.9%). However, 10 cases were RAS tissue mutant and plasma wild-type, and additional 10 cases were tissue wild-type and plasma mutant, resulting in a concordance rate of 78.3%. Analysis of plasma samples with ddPCR detected RAS mutations in 2/10 tissue mutant, plasma wild-type patients. In contrast, in all tissue wild-type and plasma mutant cases, ddPCR or deep-sequencing analysis of tumor tissue confirmed the presence of RAS mutations at allelic frequencies ranging between 0.15% and 1.15%. The median progression-free survival of RAS mutant and wild-type patients according to tissue (7.9 versus 12.6 months; P = 0.004) and liquid biopsy testing (7.8 versus 13.8 moths; P < 0.001) were comparable. Similar findings were observed for the median overall survival of RAS mutant and wild-type patients based on tissue (22.1 versus 35.8 months; P = 0.016) and plasma (19.9 versus 35.8 months; P = 0.013) analysis. CONCLUSION: This study indicates that RAS testing of liquid biopsy results in a similar outcome when compared with tissue testing in mCRC patients receiving first-line anti-EGFR monoclonal antibodies.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Normanno N, Esposito Abate R, Lambiase M, et al. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Ann Oncol. 2018. PMID: 28950295. doi:10.1093/annonc/mdx417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。